{"entity":{"id":"nct07535437","kind":"trial","name":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer","aka":[],"tldr":"A phase 1/2 trial of ivonescimab, datopotamab deruxtecan and osimertinib in lung cancer, run by Memorial Sloan Kettering Cancer Center, now recruiting.","summary":"A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer is a phase 1/2, interventional study registered as NCT07535437 by Memorial Sloan Kettering Cancer Center, with a registry enrolment figure of 66 participants, started 2026-04-09 and due to reach its primary completion in 2028-04. Interventions recorded: Ivonescimab; Dato-DXd; Osimertinib. Conditions listed: Non-Small Cell Lung Cancer. Primary outcome: determine the maximum tolerated dose (MTD) (phase I); progression free survival (phase I); measure objective response rate (ORR) (phase II). Lung eligibility wording from the registry: \"* Biopsy-proven metastatic non-small cell lung cancer\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07535437","url":"https://clinicaltrials.gov/study/NCT07535437"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["egfr-mutant-nsclc"],"sections":[],"technologies":["adc","antiangiogenic","bispecific-antibody","checkpoint-inhibitor","kinase-inhibitors"],"targets":[],"drugs":["ivonescimab","datopotamab-deruxtecan","osimertinib"],"companies":["summit-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07535437","phase":"1/2","setting":"A Phase 1/2 Trial of Ivonescimab With Dato-DXd or Osimertinib in Patients With Metastatic EGFR-mutant Non-small Cell Lung Cancer That Progressed on EGFR TKI Therapy","sponsor":"Memorial Sloan Kettering Cancer Center","enrolled":66,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07535437/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"}],"technology":[{"id":"antiangiogenic","kind":"technology","name":"Anti-angiogenic therapy","route":"/technologies/antiangiogenic/"},{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"datopotamab-deruxtecan","kind":"drug","name":"Datopotamab deruxtecan","route":"/drugs/datopotamab-deruxtecan/"},{"id":"ivonescimab","kind":"drug","name":"Ivonescimab","route":"/drugs/ivonescimab/"},{"id":"osimertinib","kind":"drug","name":"Osimertinib","route":"/drugs/osimertinib/"}],"company":[{"id":"summit-therapeutics","kind":"company","name":"Summit Therapeutics","route":"/companies/summit-therapeutics/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}